Synaptogenix Soars 6.32% on Crypto Strategy, FDA Trial

On June 10, 2025, Synaptogenix's stock surged by 6.32% in pre-market trading, marking a significant uptick in investor interest and confidence in the company's strategic initiatives.

Synaptogenix has recently made a bold move by appointing a crypto expert to lead its digital asset treasury strategy, with a focus on acquiring Bittensor's TAO token. This strategic shift involves an initial $10 million investment in TAO tokens, which is more than double the company's current market valuation. The company aims to generate revenue through staking yield and token appreciation, with a total target of $100 million in TAO tokens. This initiative is part of a broader plan to merge decentralized AI with cryptocurrency, under the strategic leadership of James Altucher.

In addition to its cryptocurrency strategy, Synaptogenix has also secured $5.5 million in financing through a Series D convertible preferred stock offering. This capital will be used to fund the company's new cryptocurrency treasury strategy and for general corporate purposes. The company has also formed a Special Committee to explore strategic opportunities for value creation, leveraging its strong balance sheet and cash reserves.

Synaptogenix's focus on innovative therapies for neurodegenerative disorders remains a key driver of its growth. The company has received FDA authorization for an Investigational New Drug (IND) application to conduct a clinical trial on Bryostatin-1, a potential treatment for multiple sclerosis. This trial will evaluate the drug's effects on synaptic health and cognitive function, with preclinical data showing promising results. Additionally, Synaptogenix has announced a new collaboration with LSU Health New Orleans to study its proprietary analogs in treating spinal cord injury, further expanding its research portfolio.